Gilead says COVID drug remdesivir shows antiviral activity against Omicron, other variants

Gilead Sciences Inc's drug, remdesivir, showed antiviral activity against Omicron, Delta and other variants of the coronavirus in laboratory studies, the company said on Friday. The study results showed similar activity of remdesivir against the variants and an early ancestral strain of the virus detected in Seattle, Washington, Gilead said. Remdesivir, marketed as Veklury, was approved by the FDA in October 2020 to treat hospitalized COVID-19 patients. Last month, this was expanded to non-hospitalized patients who were at high risk of severe disease